AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890)...

Related Keywords

Puerto Rico ,Illinois ,United States ,Chicago ,America ,American ,Coll Cardiol ,Michael Strapazon ,Jessica Akopyan ,Michellel Odonoghue ,Clin Lipidol ,Arterioscler Thromb Vasc ,Davidm Reese ,Instagram ,Amgen ,Linkedin ,Twitter ,American Heart Association Scientific Sessions ,Science Session Of The American Heart Association ,Therapeutics Inc ,Teneobio Inc ,Kyowa Kirin Co Ltd ,Drug Administration ,Beigene Ltd ,Most Sustainable Companies ,Exchange Commission ,Youtube ,Study Group At Brigham ,Chemocentryx Inc ,Olpasiran Reduced Lipoprotein ,More Than ,Patients With Established ,Outcomes Trial Based ,Simultaneously Published ,New England Journal ,Breaking Science Session ,American Heart Association ,Scientific Sessions ,Senior Investigator ,Global Principal ,Olpasiran Trials ,Cardiovascular Events And Lipoprotein ,Dow Jones Industrial Average ,Five Prime Therapeutics ,With Small Interfering ,Thromb Vasc ,Thousand Oaks ,